Immunological Therapy of Breast Cancer: Current Status and Future Potential

Joseph A. Sparano, Kevin O’Boyle

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Clinical trials of immunotherapy in patients with breast cancer have been limited. Although immune function does not appear to be depressed in patients with operable breast cancer, immune function may play a role in preventing tumour recurrence in such patients. For example, 2 features associated with an adverse prognosis include peripheral blood lymphocytopenia and lack of reactivity against autologous tumour in skin windows. A number of agents that specifically or nonspecifically augment immunity have been studied. These include levamisole, the interferons, interleukin-2, cyclosporin, tumour vaccines, monoclonal antibodies and immunotoxins. Most of these trials have involved treatment of patients with advanced disease, and little antineoplastic activity has been demonstrated in this setting. Randomised trials have found no proven benefit for treatment with interferon-α or levamisole in addition to standard chemotherapy in patients with breast cancer, although these agents may not have been used optimally in these studies. Improved understanding of the biology of breast cancer is likely to result in more rationally designed biological therapies employing entirely new treatment strategies, or using currently available drugs more effectively. Furthermore, levamisole combined with fluorouracil in patients with Duke’s C colon cancer can result in an improved outcome when compared with fluorouracil alone. This suggests that carcinomas of glandular origin may be immunologically responsive, and that it may be possible to produce clinical benefit with immunological therapies even if the precise basis for the benefit has not been defined.

Original languageEnglish (US)
Pages (from-to)135-147
Number of pages13
JournalClinical Immunotherapeutics
Volume1
Issue number2
DOIs
StatePublished - 1994

Fingerprint

Breast Neoplasms
Levamisole
Fluorouracil
Interferons
Therapeutics
Immunotoxins
Lymphopenia
Cancer Vaccines
Biological Therapy
Cerebral Palsy
Antineoplastic Agents
Immunotherapy
Colonic Neoplasms
Cyclosporine
Interleukin-2
Immunity
Neoplasms
Monoclonal Antibodies
Clinical Trials
Carcinoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Immunological Therapy of Breast Cancer : Current Status and Future Potential. / Sparano, Joseph A.; O’Boyle, Kevin.

In: Clinical Immunotherapeutics, Vol. 1, No. 2, 1994, p. 135-147.

Research output: Contribution to journalArticle

@article{d78927902a034dda808439d934bbb756,
title = "Immunological Therapy of Breast Cancer: Current Status and Future Potential",
abstract = "Clinical trials of immunotherapy in patients with breast cancer have been limited. Although immune function does not appear to be depressed in patients with operable breast cancer, immune function may play a role in preventing tumour recurrence in such patients. For example, 2 features associated with an adverse prognosis include peripheral blood lymphocytopenia and lack of reactivity against autologous tumour in skin windows. A number of agents that specifically or nonspecifically augment immunity have been studied. These include levamisole, the interferons, interleukin-2, cyclosporin, tumour vaccines, monoclonal antibodies and immunotoxins. Most of these trials have involved treatment of patients with advanced disease, and little antineoplastic activity has been demonstrated in this setting. Randomised trials have found no proven benefit for treatment with interferon-α or levamisole in addition to standard chemotherapy in patients with breast cancer, although these agents may not have been used optimally in these studies. Improved understanding of the biology of breast cancer is likely to result in more rationally designed biological therapies employing entirely new treatment strategies, or using currently available drugs more effectively. Furthermore, levamisole combined with fluorouracil in patients with Duke’s C colon cancer can result in an improved outcome when compared with fluorouracil alone. This suggests that carcinomas of glandular origin may be immunologically responsive, and that it may be possible to produce clinical benefit with immunological therapies even if the precise basis for the benefit has not been defined.",
author = "Sparano, {Joseph A.} and Kevin O’Boyle",
year = "1994",
doi = "10.1007/BF03258499",
language = "English (US)",
volume = "1",
pages = "135--147",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Immunological Therapy of Breast Cancer

T2 - Current Status and Future Potential

AU - Sparano, Joseph A.

AU - O’Boyle, Kevin

PY - 1994

Y1 - 1994

N2 - Clinical trials of immunotherapy in patients with breast cancer have been limited. Although immune function does not appear to be depressed in patients with operable breast cancer, immune function may play a role in preventing tumour recurrence in such patients. For example, 2 features associated with an adverse prognosis include peripheral blood lymphocytopenia and lack of reactivity against autologous tumour in skin windows. A number of agents that specifically or nonspecifically augment immunity have been studied. These include levamisole, the interferons, interleukin-2, cyclosporin, tumour vaccines, monoclonal antibodies and immunotoxins. Most of these trials have involved treatment of patients with advanced disease, and little antineoplastic activity has been demonstrated in this setting. Randomised trials have found no proven benefit for treatment with interferon-α or levamisole in addition to standard chemotherapy in patients with breast cancer, although these agents may not have been used optimally in these studies. Improved understanding of the biology of breast cancer is likely to result in more rationally designed biological therapies employing entirely new treatment strategies, or using currently available drugs more effectively. Furthermore, levamisole combined with fluorouracil in patients with Duke’s C colon cancer can result in an improved outcome when compared with fluorouracil alone. This suggests that carcinomas of glandular origin may be immunologically responsive, and that it may be possible to produce clinical benefit with immunological therapies even if the precise basis for the benefit has not been defined.

AB - Clinical trials of immunotherapy in patients with breast cancer have been limited. Although immune function does not appear to be depressed in patients with operable breast cancer, immune function may play a role in preventing tumour recurrence in such patients. For example, 2 features associated with an adverse prognosis include peripheral blood lymphocytopenia and lack of reactivity against autologous tumour in skin windows. A number of agents that specifically or nonspecifically augment immunity have been studied. These include levamisole, the interferons, interleukin-2, cyclosporin, tumour vaccines, monoclonal antibodies and immunotoxins. Most of these trials have involved treatment of patients with advanced disease, and little antineoplastic activity has been demonstrated in this setting. Randomised trials have found no proven benefit for treatment with interferon-α or levamisole in addition to standard chemotherapy in patients with breast cancer, although these agents may not have been used optimally in these studies. Improved understanding of the biology of breast cancer is likely to result in more rationally designed biological therapies employing entirely new treatment strategies, or using currently available drugs more effectively. Furthermore, levamisole combined with fluorouracil in patients with Duke’s C colon cancer can result in an improved outcome when compared with fluorouracil alone. This suggests that carcinomas of glandular origin may be immunologically responsive, and that it may be possible to produce clinical benefit with immunological therapies even if the precise basis for the benefit has not been defined.

UR - http://www.scopus.com/inward/record.url?scp=84950401976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950401976&partnerID=8YFLogxK

U2 - 10.1007/BF03258499

DO - 10.1007/BF03258499

M3 - Article

AN - SCOPUS:84950401976

VL - 1

SP - 135

EP - 147

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 2

ER -